Cargando…
Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study
BACKGROUND: Non-metastatic breast cancer treatment is mainly based on surgery, with or without chemotherapy, radiotherapy and/or hormone therapy. To reduce the risk of hormone receptor positive (HR+) disease recurrence, hormone therapy is prescribed for at least 5 years. It may induce adverse drug r...
Autores principales: | Gernier, François, Grellard, Jean-Michel, Dupont, Charlotte, Castel, Hervé, Fernette, Marie, Lahaye, François, Charles, Rose-Marie, Leroux, Tiphaine, Ory, Céline, Faveyrial, Audrey, Morel, Adeline, Emile, George, Levy, Christelle, Segura, Carine, Allouache, Djelila, Johnson, Alison, Geffrelot, Julien, Gunzer, Katharina, Lelaidier, Anaïs, Girault, Gilles, Dubot-poitelon, Coraline, San, Chankannira, Lequesne, Justine, Clarisse, Bénédicte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413707/ https://www.ncbi.nlm.nih.gov/pubmed/37559004 http://dx.doi.org/10.1186/s12885-023-11242-1 |
Ejemplares similares
-
Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors
por: Rottier, Pauline, et al.
Publicado: (2023) -
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
por: Cherifi, François, et al.
Publicado: (2022) -
LBA69 Impact of the COVID-19 pandemic on management of medical cancer treatments and psychological consequence for the patients
por: Joly, F., et al.
Publicado: (2020) -
Does COVID‐19 pandemic impact cancer outcomes in metastatic setting? A comparative cohort study among metastatic patients treated at day care hospital
por: Quilan, Florian, et al.
Publicado: (2023) -
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
por: Lesueur, Paul, et al.
Publicado: (2019)